Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $6.54.

A number of brokerages have issued reports on INO. BidaskClub downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, May 3rd. HC Wainwright reiterated a “buy” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, May 7th. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Thursday, February 14th.

Shares of INO stock opened at $3.49 on Thursday. Inovio Pharmaceuticals has a 52-week low of $3.02 and a 52-week high of $6.30. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 1.02. The stock has a market capitalization of $349.98 million, a price-to-earnings ratio of -3.32 and a beta of 1.70.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.01). Inovio Pharmaceuticals had a negative return on equity of 97.95% and a negative net margin of 295.24%. The firm had revenue of $2.83 million during the quarter, compared to the consensus estimate of $4.44 million. On average, equities analysts expect that Inovio Pharmaceuticals will post -0.99 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INO. SG Americas Securities LLC purchased a new position in Inovio Pharmaceuticals in the first quarter valued at about $40,000. Quantamental Technologies LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at approximately $43,000. Amalgamated Bank purchased a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at approximately $50,000. Pembroke Management LTD purchased a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at approximately $52,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at approximately $58,000. Hedge funds and other institutional investors own 40.50% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Article: Capital gains and your 401(k) or IRA

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.